Abstract: New N-Arylalkylderivatives of 2-aminomethyl-2,3-dihydro-1,4-benzodioxine and its (+)- and (-)- enantiomers represented by general formula (I), where R.sub.1, R.sub.2 and R.sub.3 represent H, or R.sub.1 and R.sub.2 represent H and R.sub.3 represent H or R.sub.1 and R.sub.2 represent methoxy and R.sub.3 represents H and their pharmaceutically acceptable organic or inorganic acid addition salts exhibit in pharmacological tests pronounced hypotensive activity as a result of their calcium channel blocking and alpha.sub.1 -adrenergic blocking activity and pronounced antithrombotic action. In a form of pharmaceutical preparations, they are suitable for the treatment and prevention of cardiovascular diseases and other disorders.

Abstract: The present application is directed to a method of treating central nervous system disorders originating as a consequence of head injury or brain ischemia. The method comprises administering an effective amount of cyclo-(L-alanyl-1-amino-1-cyclopentane carbonyl) to treat a central nervous system disorder in a mammalian organism in need of such treatment. The administration may be conducted either orally or parenterally.

Abstract: This invention relates to 5-[4-[-(4,6-dimethyl-2-pyrimidinylsulfamoyl)phenylazo]acetylsalicylic acid (DISALAZINE) is provided as a new compound having anti-arthritic and immunomodulating properties. It can be produced via reaction of the diazonium salt of sulfadimidine reacted with salicylic acid and then acetylating the product anti-arthritic and immunomodulating properties.